Considerations on future treatment of POMS

The rapidly evolving landscape of DMTS presents significant challenges for the development and testing of new treatments in children, including the need to recruit sufficient numbers randomized trials, the time and cost involved, and the risk that trials conducted using older medications may become obsolete by the time they are completed

Current treatment algorithms in POMS remain reliant on adult MS protocols

Convincing evidence has increasingly emerged to support the biological rationale that effective DMTs in adult patients with MS are equally efficacious in children

Based on the existing evidence on the beneficial effect of treatments with high efficacy in reducing disease activity and progressionit is essential to consider the window of opportunity in children with MS to initiate early effective treatment, as this has the potential to improve their long-term outcomes

Abdel-Mannan O et al, Neurology 2022